OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Bridging data and drug development: Machine learning approaches for next-generation ADMET prediction	262
General aspects of powder rheology applied to pharmaceutical formulations	230
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	203
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	194
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	193
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	183
On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives	149
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	143
Computational modeling approaches and regulatory pathways for drug combinations	131
Tubulin targeting agents and their implications in non-cancer disease management	125
Models and approaches to comprehend and address glial inflammation following spinal cord injury	120
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	119
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	117
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	117
Gastroretentive drug delivery systems: A holy grail in oral delivery	113
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	97
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	95
Antibody–drug conjugates: What drives their progress?	94
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	92
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	91
Contents page	86
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	85
The recent progress of deep-learning-based in silico prediction of drug combination	84
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	84
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	84

CIPDB: A biological structure databank for studying cation and π interactions	83
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	82
The potential value of 5-androstenediol in countering acute radiation syndrome	82
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	80
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	78
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	76
Caught between a ROCK and a hard place: current challenges in structure-based drug design	76
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options	74
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	74
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	72
Gaps between medical biology and AI drug discovery	71
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	70
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	67
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	67
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	66
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	64
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	63
Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges	62
Lactose in tablets: Functionality, critical material attributes, applications, modifications and co-processed excipients	62
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	62
Pathogenic TDP-43 in amyotrophic lateral sclerosis	61
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	61
ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality	61
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	60
Molecular approaches for the treatment and prevention of Friedreich's ataxia	59
MRI assessment of cerebral perfusion in clinical trials	59
Recent advances towards overcoming the blood–brain barrier	59
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	58
Steps toward nebulization in-use studies to understand the stability of new biological entities	58
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	58
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	57
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	57